BHC:CA:TSX-Bausch Health Companies Inc (CAD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | TSX

Last Closing Price

CAD 20.49

Change

0.00 (0.00)%

Market Cap

CAD 7.27B

Volume

0.43M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. Address: 2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
WEED:CA Canopy Growth Corporation

N/A

CAD7.03B N/A N/A
CRON:CA Cronos Group Inc

N/A

CAD2.38B 2.45 N/A
APHA:CA Aphria Inc

N/A

CAD1.63B 57.08 525.23
GUD:CA Knight Therapeutics Inc

N/A

CAD0.78B 122.45 11.93
ACB:CA Aurora Cannabis Inc

N/A

CAD0.76B 1,171.00 N/A
CWEB:CA Charlotte's Web Holdings, Inc

N/A

CAD0.46B 120.37 N/A
HLS:CA HLS Therapeutics Inc

N/A

CAD0.43B N/A 29.93
HEXO:CA HEXO Corp

N/A

CAD0.42B N/A N/A
NEPT:CA Neptune Wellness Solutions Inc

N/A

CAD0.32B 32.20 N/A
OGI:CA OrganiGram Holdings Inc

N/A

CAD0.28B -99,999.99 N/A

ETFs Containing BHC:CA

Symbol Name Weight Mer Price(Change) Market Cap
CJNK SPDR ICE BofAML Broad Hig.. 0.00 % 0.15 %

N/A

CAD0.07B
FBE:CA CI First Asset Canadian B.. 0.00 % 0.60 %

N/A

CAD7.44M
QXM:CA CI First Asset Morningsta.. 0.00 % 0.50 %

N/A

CAD0.06B
XFC:CA iShares MSCI Multifactor .. 0.00 % 0.45 %

N/A

CAD0.04B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.29% 41% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.29% 41% F 8% F
Trailing 12 Months  
Capital Gain -28.76% 73% C 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.76% 73% C 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.17% N/A N/A 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.17% N/A N/A 18% F
Risk Return Profile  
Volatility (Standard Deviation) 16.52% N/A N/A 45% F
Risk Adjusted Return -19.20% N/A N/A 24% F
Market Capitalization 7.27B 100% A+ 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 12.98 4% F 5% F
Price / Cash Flow Ratio 4.85 11% F 61% D-
EV/EBITDA 27.89 36% F 16% F
Management Effectiveness  
Return on Equity -126.28% 7% F 6% F
Return on Invested Capital -0.71% 79% C+ 35% F
Return on Assets 2.24% 89% B+ 61% D-
Debt to Equity Ratio 2,319.94% 5% F 1% F
Technical Ratios  
Short Ratio 4.87 39% F 21% F
Short Percent 1.00% 75% C 90% A-
Beta 1.14 77% C+ 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector